Cytonus Therapeutics

$14.4M disclosed across 5 rounds · 2018–2023

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

AG

Agenus17 shared keywords

AM

Amicus Therapeutics16 shared keywordsAmicus is a rare disease biotechnology company developing medicines for people with genetically defined conditions. It operates as a wholly owned subsidiary of BioMarin Pharmaceutical Inc.

TA

Talus Bio15 shared keywordsTalus develops a proprietary platform that measures and modulates the regulome—the body's gene expression control system—in native cellular contexts. The company designs AI-driven compounds and uses functional proteomics to enable drug discovery for transcription factors and regulatory proteins implicated in oncology, rare disease, and immune dysfunction.

CY

Cytonics15 shared keywordsCytonics develops A2M-based biologic therapies for osteoarthritis, including its lead candidate CYT-108, a "super A2M" drug in FDA clinical trials that targets enzymes responsible for cartilage degradation. The company aims to create the first disease-modifying therapy for osteoarthritis rather than treating only symptoms.

CO

Coherus Biosciences12 shared keywordsCoherus Oncology develops and commercializes immuno-oncology therapies, including the approved LOQTORZI, to treat patients with cancer. The company focuses on expanding its pipeline of clinical-stage candidates targeting the tumor microenvironment.

Companies competing with Cytonus Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.